Skip to content

The use of sildenafil in patients with univentricular heart after Fontan operation - a pilot SINFON-POL study.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503913-31-01
Acronym
2.16/VI/22
Enrollment
60
Registered
2024-09-22
Start date
2025-06-27
Completion date
Unknown
Last updated
2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, and in multi-centre studies. Among other things, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, Fontan circulation is created, Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart., i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, it is not possible to correct the intracardiac defect. Then, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, pulmonary resistance in these patients should be not only normal, reduced initial depression of a single ventricle, there are indications for the Fontan operation, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, which undoubtedly extends the survival of children born with this heart defect

Brief summary

Increase in peak oxygen uptake (V02max) in ergospirometry test after 24 weeks of treatment

Detailed description

Increase in the amount of exercise performed, measured in metabolic equivalents (METS) during cardiopulmonary exercise testing (CPET) after 24 weeks of treatment, Increase in the distance covered in the 6-minute walk test (6MWT), Increase in the absolute value of global longitudinal strain (GLS) in echocardiography after 24 weeks of treatment, Reduction in serum Nt-proBNP levels after 24 weeks of treatment, Reduction in fibrosis score on elastography (abdominal ultrasound) after 24 weeks of treatment, Increase in the quality of life index as assessed by the SF-36 questionnaire after 24 weeks of treatment

Interventions

DRUGSildenafil placebo
DRUGRemidia
DRUG20 mg

Sponsors

National Institute Of Cardiology
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Increase in peak oxygen uptake (V02max) in ergospirometry test after 24 weeks of treatment

Secondary

MeasureTime frame
Increase in the amount of exercise performed, measured in metabolic equivalents (METS) during cardiopulmonary exercise testing (CPET) after 24 weeks of treatment, Increase in the distance covered in the 6-minute walk test (6MWT), Increase in the absolute value of global longitudinal strain (GLS) in echocardiography after 24 weeks of treatment, Reduction in serum Nt-proBNP levels after 24 weeks of treatment, Reduction in fibrosis score on elastography (abdominal ultrasound) after 24 weeks of treatment, Increase in the quality of life index as assessed by the SF-36 questionnaire after 24 weeks of treatment

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026